Providing the 'on' switch for immuno-oncology Replimune is developing novel, proprietary oncolytic immunotherapies intended to improve both the direct anti-tumor effects of selective virus replication and the potency of the immune response to the tumor antigens released.
[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=”https://www.linkedin.com/company/replimune-limited” connections=”true” suffix=””]
Replimunes Immulytic_ platform consists of potent proprietary herpes simplex virus (HSV) strain to directly kill cancer cells and deliver additional therapeutic proteins into tumors, with enhanced tumor killing and spread.
In Sep 2017, Replimune raised $55 Mn Series B financing, led by Foresite Capital who were joined by other new investors including Bain Capital Life Sciences, Redmile Group, Cormorant Asset Management and entities affiliated with Leerink Partners. All of the Companys existing investors; Atlas Venture, Forbion Capital Partners, and Omega Funds, also meaningfully participated.
In Sep 2015, Replimune Ltd. announced closing of $30 Mn series A financing led by Atlas Venture. Atlas joins previous seed investors Forbion Capital Partners (Forbion) and Omega Funds (Omega) as investors in this funding round.